Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMSA 101

Next Previous
Drug Profile

IMSA 101

Alternative Names: GB-492; IMSA-101

Latest Information Update: 16 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneSensor
  • Developer Genor Biopharma; ImmuneSensor
  • Class Antineoplastics; Small molecules
  • Mechanism of Action STING1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Renal cell carcinoma
  • Phase I/II Solid tumours

Most Recent Events

  • 09 Dec 2024 ImmuneSensor Therapeutics terminates a phase II trial for Solid tumors (Second-line therapy or greater, Combination therapy, Metastatic disease, Late-stage disease) in the US, due to the change in ImmuneSensor corporate strategy (NCT05846659)
  • 19 Sep 2024 University of Texas Southwestern Medical Center plans a phase II SPARK trial for Renal cell carcinoma (Metastatic disease) in USA in October 2024 (NCT06601296)
  • 16 Sep 2024 ImmuneSensor Therapeutics terminates a phase II trial for Non small cell lung cancer and Renal cell carcinoma (Metastatic disease, Combination therapy) (Intratumoural, Injection) due to slow enrollment (NCT05846646)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top